Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case report, a nearly 12-year-old boy with alopecia universalis and atopic dermatitis experienced full hair regrowth and improved dermatitis following treatment with upadacitinib, a JAK 1 inhibitor, showing notable positive effects on his psychological well-being and family.

This review discusses the potential of dupilumab for treating alopecia areata, reporting mixed outcomes with both improvement and new-onset hair loss observed in case reports.

This case report highlights that a patient developed alopecia areata following treatment with sofosbuvir and ribavirin for chronic hepatitis C.

This review provides a synopsis of 53 cases of temporal triangular alopecia, noting its frequent detection in early childhood and potential association with congenital diseases, but it reports no new clinical findings.

This study is collecting real-world data to evaluate abrocitinib and conventional systemic treatments in moderate-to-severe atopic dermatitis across five European registers over a three-year period.

This article is a letter to the editor about high-dose pulsed corticosteroid therapy combined with methotrexate for severe childhood alopecia areata and provides no new clinical results.

In this study, the researchers reported that baricitinib improved hair loss in a real-world setting for Japanese adults with alopecia areata, with a 64.7% success rate at 60 weeks, though prolonged episodes reduced efficacy. Common side effects were acne and mildly decreased renal function.

This study examines how the Severity of Alopecia Tool score was used to assess Alopecia Areata in patients while excluding systemic conditions that might affect vitamin D levels, but reports no new clinical results.

In this study, the authors reported that while conventional treatment improved rickets in a boy with vitamin D-dependent rickets type II, it also resulted in unexpected improvement in his alopecia.

Alopecia areata often recurs after treatment with diphenylcyclopropenone.

This study will evaluate the clinical efficacy, patient-reported outcomes, and economic impact of the PAXMAN® PSCS 2 automated scalp cooling system versus standard cold-cap therapy to prevent chemotherapy-induced hair loss in women with localized breast cancer during anthracycline and taxane treatment.

This study identified a missense variant in the EDA gene of a male cat, which likely caused hypohidrotic ectodermal dysplasia, characterized by hair and teeth abnormalities; this represents the first report of such a genetic condition in cats.

This review examines the reliance on formalized and automated protocols in fields like aviation and medicine, suggesting that such approaches may hinder the human capability of mètis needed to handle emergencies and dynamic ambiguities; it reports no new results.

In this open-label study of post-menopausal women with frontal fibrosing alopecia, researchers found that 12 weeks of baricitinib monotherapy significantly reduced disease activity as measured by the Lichen Planopilaris Activity Index, improved patient-reported scalp hair growth, but showed no significant change in eyebrow growth.

In this review, the potential medicinal benefits of Adiantum capillus-veneris L. (a plant used in traditional medicine) were highlighted, particularly its antioxidant, antimicrobial, and anti-inflammatory effects, although the authors noted the need for more research on its impact on respiratory diseases.

This study found that dimethylpabamidopropyl laurdimonium tosylate, a quaternary ammonium surfactant, adsorbs onto human scalp hair with kinetic and isotherm behaviors fitting specific models, changing hair fiber wettability from hydrophobic to hydrophilic.

This study found that baricitinib, when administered consistently over three years, maintained its efficacy in patients with severe alopecia areata who responded by Week 52 with notable hair regrowth, indicated by a SALT score of ≤20.

This study found that Arabidopsis thaliana plants developed longer root hairs under low phosphorus conditions, suggesting auxin involvement in this adaptive response.

In this case study, a 5-year-old girl with alopecia areata and atopic dermatitis that were unresponsive to previous treatments achieved substantial improvement with long-term tofacitinib, highlighting its potential safety and efficacy in managing both conditions concurrently.

This study found that twice-daily oral baricitinib at a 2-mg dose showed promising results in treating refractory alopecia areata, particularly among Chinese patients, with 64% achieving significant hair regrowth, although none attained complete hair regrowth. Adverse events were mild and included nausea and folliculitis.

The document's conclusion cannot be determined from the provided text.

In this study involving children with alopecia areata, researchers found that adding narrowband UVB 311 nm therapy to standard treatment significantly improved hair regrowth in those with coexisting atopic dermatitis compared to those without the condition.

In this analysis of two trials, baricitinib showed eyebrow and eyelash regrowth in severe alopecia areata patients with greater than 20% scalp hair loss at Week 36, compared to placebo.

In this study, UPA at doses of 15 mg and 30 mg showed higher efficacy than placebo for treating severe alopecia areata in adults and adolescents over 24 weeks, with a safety profile similar to approved uses.

In this study, researchers evaluated CS12192, a selective JAK3 inhibitor, in an alopecia areata mouse model and found it reversed hair growth inhibition comparably to baricitinib, with better safety and similar immune-modulating mechanisms.

This review discusses the clinical challenges in treating alopecia areata with off-label therapies, highlighting the need to consider new research on JAK inhibitors, but reports no new clinical results.

Baricitinib is a safe and effective treatment for severe alopecia areata.

This study reported improvement in an 11-year-old boy with refractory alopecia areata after 4 months of treatment with oral abrocitinib, a JAK1 inhibitor, suggesting it may be a potential alternative for pediatric patients unresponsive to conventional therapies.

This study found that dihydrotestosterone induces hair loss in male C57BL/6 mice, and this effect can be partially reversed by the androgen receptor antagonist bicalutamide.

This case report documents a successful treatment of alopecia areata using Ayurvedic management, suggesting that Ayurveda could help restore balance and promote hair regrowth in this autoimmune condition.